London-headquartered Spex Capital has launched a new healthtech fund of €100 million. The fund will back innovations overcoming global healthcare challenges.
Healthtech continues to be a growing market. Innovations and solutions that better healthcare, on a personal and global level, create impact for people and also represent an incredibly lucrative space. Europe’s healthtech ecosystem is growing, benefiting from strong links to public health organisations and universities. According to PitchBook data, €5 billion was invested in healthtech in 2022 in Europe, and this year the funds already rolling in.
Today, digital health and medtech investors Spex Capital have announced a new fund to fuel more growth in the sector – planning to pump €100 million into the market.
Founded in 2021 by Claudio D’Angelo, Spex Capital backs disruptive early-stage ventures that are aiming to positively influence healthcare systems globally, with breakthrough technology.
The firm, which is headquartered in London, also leverages an ongoing partnership with MedCity, the organisation that represents London’s life sciences cluster. it collaborates with the city’s academic centres to connect private industry with partners in the NHS, the charity sector and research institutes. Joint activities include an international investment programme that contributes to the flow of around 1,000 healthcare companies developing breakthrough technologies every year.
With this new fund, Spex Capital aims to accelerate the adoption of tech in global healthcare. The fund has a target size of €100 million and will invest from seed to Series A, up to a ticket size of €5 million. The fund is a designated Article 9 impact fund under the EU’s Sustainable Finance Disclosure Regulation (SFDR).
Claudio D’Angelo, Founder and CEO of Spex Capital, said: “Even before Covid-19, the drive for countries to make better use of digital technology in healthcare had already begun. With this fund, our partnership with MedCity, and a broad network of high calibre Senior Advisors, we will have unparalleled access to invest in the best startups within this space.”
So far, Spex has closed 10 investments in the healthtech space. This new fund will enhance its global reach and fuel new innovations in healthcare.
Brent Stackhouse, Senior Partner, Mount Sinai Ventures, said: “I’m excited to take part in the launch of the Spex Venture HealthTech Fund at a time of radical change for the healthtech sector. History has shown us time and time again that economic downturns provide an impetus for innovation and that some of the strongest vintages have come from recession years. We now have an opportunity to acquire high-quality assets at discounted valuations. We look forward to shaping the global healthcare ecosystem by helping innovators in developing ground-breaking technologies and solutions to overcome healthcare challenges worldwide.”